Global Wet Macular Degeneration Market 2021 by Company, Regions, Type and Application, Forecast to 2026

Page: 122

Published Date: 29 Jan 2021

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The Wet Macular Degeneration market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Wet Macular Degeneration size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Wet Macular Degeneration market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Wet Macular Degeneration market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Lucentis
Eylea
Avastin
Others

Market segment by Application, can be divided into
Hospitals
Clinics
Research Institutes
Academic Institutes

Market segment by players, this report covers
Pfizer Inc.
F. Hoffmann-La Roche AG
Regeneron Pharmaceuticals, Inc.
Novartis AG
Bausch Health Companies Inc.
Apellis Pharmaceuticals Inc.
GlaxoSmithKline plc
Ophthotech Corporation
Gilead Sciences, Inc.
Alcon
Genzyme Corporation
Boehringer Ingelheim GmbH
EyeGate Pharmaceuticals, Inc.
EyeCyte, Inc.
PanOptica Inc

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Wet Macular Degeneration
    1.2 Classification of Wet Macular Degeneration by Type
        1.2.1 Overview: Global Wet Macular Degeneration Market Size by Type: 2020 Versus 2021 Versus 2026
        1.2.2 Global Wet Macular Degeneration Revenue Market Share by Type in 2020
        1.2.3 Lucentis
        1.2.4 Eylea
        1.2.5 Avastin
        1.2.6 Others
    1.3 Global Wet Macular Degeneration Market by Application
        1.3.1 Overview: Global Wet Macular Degeneration Market Size by Application: 2020 Versus 2021 Versus 2026
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Research Institutes
        1.3.5 Academic Institutes
    1.4 Global Wet Macular Degeneration Market Size & Forecast
    1.5 Global Wet Macular Degeneration Market Size and Forecast by Region
        1.5.1 Global Wet Macular Degeneration Market Size by Region: 2016 VS 2021 VS 2026
        1.5.2 Global Wet Macular Degeneration Market Size by Region, (2016-2021)
        1.5.3 North America Wet Macular Degeneration Market Size and Prospect (2016-2026)
        1.5.4 Europe Wet Macular Degeneration Market Size and Prospect (2016-2026)
        1.5.5 Asia-Pacific Wet Macular Degeneration Market Size and Prospect (2016-2026)
        1.5.6 South America Wet Macular Degeneration Market Size and Prospect (2016-2026)
        1.5.7 Middle East and Africa Wet Macular Degeneration Market Size and Prospect (2016-2026)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 Wet Macular Degeneration Market Drivers
        1.6.2 Wet Macular Degeneration Market Restraints
        1.6.3 Wet Macular Degeneration Trends Analysis

2 Company Profiles
    2.1 Pfizer Inc.
        2.1.1 Pfizer Inc. Details
        2.1.2 Pfizer Inc. Major Business
        2.1.3 Pfizer Inc. Wet Macular Degeneration Product and Solutions
        2.1.4 Pfizer Inc. Wet Macular Degeneration Revenue, Gross Margin and Market Share (2019-2021)
        2.1.5 Pfizer Inc. Recent Developments and Future Plans
    2.2 F. Hoffmann-La Roche AG
        2.2.1 F. Hoffmann-La Roche AG Details
        2.2.2 F. Hoffmann-La Roche AG Major Business
        2.2.3 F. Hoffmann-La Roche AG Wet Macular Degeneration Product and Solutions
        2.2.4 F. Hoffmann-La Roche AG Wet Macular Degeneration Revenue, Gross Margin and Market Share (2019-2021)
        2.2.5 F. Hoffmann-La Roche AG Recent Developments and Future Plans
    2.3 Regeneron Pharmaceuticals, Inc.
        2.3.1 Regeneron Pharmaceuticals, Inc. Details
        2.3.2 Regeneron Pharmaceuticals, Inc. Major Business
        2.3.3 Regeneron Pharmaceuticals, Inc. Wet Macular Degeneration Product and Solutions
        2.3.4 Regeneron Pharmaceuticals, Inc. Wet Macular Degeneration Revenue, Gross Margin and Market Share (2019-2021)
        2.3.5 Regeneron Pharmaceuticals, Inc. Recent Developments and Future Plans
    2.4 Novartis AG
        2.4.1 Novartis AG Details
        2.4.2 Novartis AG Major Business
        2.4.3 Novartis AG Wet Macular Degeneration Product and Solutions
        2.4.4 Novartis AG Wet Macular Degeneration Revenue, Gross Margin and Market Share (2019-2021)
        2.4.5 Novartis AG Recent Developments and Future Plans
    2.5 Bausch Health Companies Inc.
        2.5.1 Bausch Health Companies Inc. Details
        2.5.2 Bausch Health Companies Inc. Major Business
        2.5.3 Bausch Health Companies Inc. Wet Macular Degeneration Product and Solutions
        2.5.4 Bausch Health Companies Inc. Wet Macular Degeneration Revenue, Gross Margin and Market Share (2019-2021)
        2.5.5 Bausch Health Companies Inc. Recent Developments and Future Plans
    2.6 Apellis Pharmaceuticals Inc.
        2.6.1 Apellis Pharmaceuticals Inc. Details
        2.6.2 Apellis Pharmaceuticals Inc. Major Business
        2.6.3 Apellis Pharmaceuticals Inc. Wet Macular Degeneration Product and Solutions
        2.6.4 Apellis Pharmaceuticals Inc. Wet Macular Degeneration Revenue, Gross Margin and Market Share (2019-2021)
        2.6.5 Apellis Pharmaceuticals Inc. Recent Developments and Future Plans
    2.7 GlaxoSmithKline plc
        2.7.1 GlaxoSmithKline plc Details
        2.7.2 GlaxoSmithKline plc Major Business
        2.7.3 GlaxoSmithKline plc Wet Macular Degeneration Product and Solutions
        2.7.4 GlaxoSmithKline plc Wet Macular Degeneration Revenue, Gross Margin and Market Share (2019-2021)
        2.7.5 GlaxoSmithKline plc Recent Developments and Future Plans
    2.8 Ophthotech Corporation
        2.8.1 Ophthotech Corporation Details
        2.8.2 Ophthotech Corporation Major Business
        2.8.3 Ophthotech Corporation Wet Macular Degeneration Product and Solutions
        2.8.4 Ophthotech Corporation Wet Macular Degeneration Revenue, Gross Margin and Market Share (2019-2021)
        2.8.5 Ophthotech Corporation Recent Developments and Future Plans
    2.9 Gilead Sciences, Inc.
        2.9.1 Gilead Sciences, Inc. Details
        2.9.2 Gilead Sciences, Inc. Major Business
        2.9.3 Gilead Sciences, Inc. Wet Macular Degeneration Product and Solutions
        2.9.4 Gilead Sciences, Inc. Wet Macular Degeneration Revenue, Gross Margin and Market Share (2019-2021)
        2.9.5 Gilead Sciences, Inc. Recent Developments and Future Plans
    2.10 Alcon
        2.10.1 Alcon Details
        2.10.2 Alcon Major Business
        2.10.3 Alcon Wet Macular Degeneration Product and Solutions
        2.10.4 Alcon Wet Macular Degeneration Revenue, Gross Margin and Market Share (2019-2021)
        2.10.5 Alcon Recent Developments and Future Plans
    2.11 Genzyme Corporation
        2.11.1 Genzyme Corporation Details
        2.11.2 Genzyme Corporation Major Business
        2.11.3 Genzyme Corporation Wet Macular Degeneration Product and Solutions
        2.11.4 Genzyme Corporation Wet Macular Degeneration Revenue, Gross Margin and Market Share (2019-2021)
        2.11.5 Genzyme Corporation Recent Developments and Future Plans
    2.12 Boehringer Ingelheim GmbH
        2.12.1 Boehringer Ingelheim GmbH Details
        2.12.2 Boehringer Ingelheim GmbH Major Business
        2.12.3 Boehringer Ingelheim GmbH Wet Macular Degeneration Product and Solutions
        2.12.4 Boehringer Ingelheim GmbH Wet Macular Degeneration Revenue, Gross Margin and Market Share (2019-2021)
        2.12.5 Boehringer Ingelheim GmbH Recent Developments and Future Plans
    2.13 EyeGate Pharmaceuticals, Inc.
        2.13.1 EyeGate Pharmaceuticals, Inc. Details
        2.13.2 EyeGate Pharmaceuticals, Inc. Major Business
        2.13.3 EyeGate Pharmaceuticals, Inc. Wet Macular Degeneration Product and Solutions
        2.13.4 EyeGate Pharmaceuticals, Inc. Wet Macular Degeneration Revenue, Gross Margin and Market Share (2019-2021)
        2.13.5 EyeGate Pharmaceuticals, Inc. Recent Developments and Future Plans
    2.14 EyeCyte, Inc.
        2.14.1 EyeCyte, Inc. Details
        2.14.2 EyeCyte, Inc. Major Business
        2.14.3 EyeCyte, Inc. Wet Macular Degeneration Product and Solutions
        2.14.4 EyeCyte, Inc. Wet Macular Degeneration Revenue, Gross Margin and Market Share (2019-2021)
        2.14.5 EyeCyte, Inc. Recent Developments and Future Plans
    2.15 PanOptica Inc
        2.15.1 PanOptica Inc Details
        2.15.2 PanOptica Inc Major Business
        2.15.3 PanOptica Inc Wet Macular Degeneration Product and Solutions
        2.15.4 PanOptica Inc Wet Macular Degeneration Revenue, Gross Margin and Market Share (2019-2021)
        2.15.5 PanOptica Inc Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Wet Macular Degeneration Revenue and Share by Players (2019-2021)
    3.2 Market Concentration Rate
        3.2.1 Top 3 Wet Macular Degeneration Players Market Share
        3.2.2 Top 10 Wet Macular Degeneration Players Market Share
        3.2.3 Market Competition Trend
    3.3 Wet Macular Degeneration Players Head Office, Products and Services Provided
    3.4 Mergers & Acquisitions
    3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type
    4.1 Global Wet Macular Degeneration Revenue and Market Share by Type (2016-2021)
    4.2 Global Wet Macular Degeneration Market Forecast by Type (2021-2026)

5 Market Size Segment by Application
    5.1 Global Wet Macular Degeneration Revenue Market Share by Application (2016-2021)
    5.2 Wet Macular Degeneration Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application
    6.1 North America Wet Macular Degeneration Revenue by Type (2016-2026)
    6.2 North America Wet Macular Degeneration Revenue by Application (2016-2026)
    6.3 North America Wet Macular Degeneration Market Size by Country
        6.3.1 North America Wet Macular Degeneration Revenue by Country (2016-2026)
        6.3.2 United States Wet Macular Degeneration Market Size and Forecast (2016-2026)
        6.3.3 Canada Wet Macular Degeneration Market Size and Forecast (2016-2026)
        6.3.4 Mexico Wet Macular Degeneration Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application
    7.1 Europe Wet Macular Degeneration Revenue by Type (2016-2026)
    7.2 Europe Wet Macular Degeneration Revenue by Application (2016-2026)
    7.3 Europe Wet Macular Degeneration Market Size by Country
        7.3.1 Europe Wet Macular Degeneration Revenue by Country (2016-2026)
        7.3.2 Germany Wet Macular Degeneration Market Size and Forecast (2016-2026)
        7.3.3 France Wet Macular Degeneration Market Size and Forecast (2016-2026)
        7.3.4 United Kingdom Wet Macular Degeneration Market Size and Forecast (2016-2026)
        7.3.5 Russia Wet Macular Degeneration Market Size and Forecast (2016-2026)
        7.3.6 Italy Wet Macular Degeneration Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific Wet Macular Degeneration Revenue by Type (2016-2026)
    8.2 Asia-Pacific Wet Macular Degeneration Revenue by Application (2016-2026)
    8.3 Asia-Pacific Wet Macular Degeneration Market Size by Region
        8.3.1 Asia-Pacific Wet Macular Degeneration Revenue by Region (2016-2026)
        8.3.2 China Wet Macular Degeneration Market Size and Forecast (2016-2026)
        8.3.3 Japan Wet Macular Degeneration Market Size and Forecast (2016-2026)
        8.3.4 South Korea Wet Macular Degeneration Market Size and Forecast (2016-2026)
        8.3.5 India Wet Macular Degeneration Market Size and Forecast (2016-2026)
        8.3.6 Southeast Asia Wet Macular Degeneration Market Size and Forecast (2016-2026)
        8.3.7 Australia Wet Macular Degeneration Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application
    9.1 South America Wet Macular Degeneration Revenue by Type (2016-2026)
    9.2 South America Wet Macular Degeneration Revenue by Application (2016-2026)
    9.3 South America Wet Macular Degeneration Market Size by Country
        9.3.1 South America Wet Macular Degeneration Revenue by Country (2016-2026)
        9.3.2 Brazil Wet Macular Degeneration Market Size and Forecast (2016-2026)
        9.3.3 Argentina Wet Macular Degeneration Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa Wet Macular Degeneration Revenue by Type (2016-2026)
    10.2 Middle East & Africa Wet Macular Degeneration Revenue by Application (2016-2026)
    10.3 Middle East & Africa Wet Macular Degeneration Market Size by Country
        10.3.1 Middle East & Africa Wet Macular Degeneration Revenue by Country (2016-2026)
        10.3.2 Turkey Wet Macular Degeneration Market Size and Forecast (2016-2026)
        10.3.3 Saudi Arabia Wet Macular Degeneration Market Size and Forecast (2016-2026)
        10.3.4 UAE Wet Macular Degeneration Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Wet Macular Degeneration Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
    Table 2. Global Wet Macular Degeneration Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
    Table 3. Global Market Wet Macular Degeneration Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
    Table 4. Global Wet Macular Degeneration Revenue (USD Million) by Region (2016-2021)
    Table 5. Global Wet Macular Degeneration Revenue Market Share by Region (2021-2026)
    Table 6. Pfizer Inc. Corporate Information, Head Office, and Major Competitors
    Table 7. Pfizer Inc. Major Business
    Table 8. Pfizer Inc. Wet Macular Degeneration Product and Solutions
    Table 9. Pfizer Inc. Wet Macular Degeneration Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 10. F. Hoffmann-La Roche AG Corporate Information, Head Office, and Major Competitors
    Table 11. F. Hoffmann-La Roche AG Major Business
    Table 12. F. Hoffmann-La Roche AG Wet Macular Degeneration Product and Solutions
    Table 13. F. Hoffmann-La Roche AG Wet Macular Degeneration Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 14. Regeneron Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
    Table 15. Regeneron Pharmaceuticals, Inc. Major Business
    Table 16. Regeneron Pharmaceuticals, Inc. Wet Macular Degeneration Product and Solutions
    Table 17. Regeneron Pharmaceuticals, Inc. Wet Macular Degeneration Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 18. Novartis AG Corporate Information, Head Office, and Major Competitors
    Table 19. Novartis AG Major Business
    Table 20. Novartis AG Wet Macular Degeneration Product and Solutions
    Table 21. Novartis AG Wet Macular Degeneration Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 22. Bausch Health Companies Inc. Corporate Information, Head Office, and Major Competitors
    Table 23. Bausch Health Companies Inc. Major Business
    Table 24. Bausch Health Companies Inc. Wet Macular Degeneration Product and Solutions
    Table 25. Bausch Health Companies Inc. Wet Macular Degeneration Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 26. Apellis Pharmaceuticals Inc. Corporate Information, Head Office, and Major Competitors
    Table 27. Apellis Pharmaceuticals Inc. Major Business
    Table 28. Apellis Pharmaceuticals Inc. Wet Macular Degeneration Product and Solutions
    Table 29. Apellis Pharmaceuticals Inc. Wet Macular Degeneration Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 30. GlaxoSmithKline plc Corporate Information, Head Office, and Major Competitors
    Table 31. GlaxoSmithKline plc Major Business
    Table 32. GlaxoSmithKline plc Wet Macular Degeneration Product and Solutions
    Table 33. GlaxoSmithKline plc Wet Macular Degeneration Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 34. Ophthotech Corporation Corporate Information, Head Office, and Major Competitors
    Table 35. Ophthotech Corporation Major Business
    Table 36. Ophthotech Corporation Wet Macular Degeneration Product and Solutions
    Table 37. Ophthotech Corporation Wet Macular Degeneration Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 38. Gilead Sciences, Inc. Corporate Information, Head Office, and Major Competitors
    Table 39. Gilead Sciences, Inc. Major Business
    Table 40. Gilead Sciences, Inc. Wet Macular Degeneration Product and Solutions
    Table 41. Gilead Sciences, Inc. Wet Macular Degeneration Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 42. Alcon Corporate Information, Head Office, and Major Competitors
    Table 43. Alcon Major Business
    Table 44. Alcon Wet Macular Degeneration Product and Solutions
    Table 45. Alcon Wet Macular Degeneration Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 46. Genzyme Corporation Corporate Information, Head Office, and Major Competitors
    Table 47. Genzyme Corporation Major Business
    Table 48. Genzyme Corporation Wet Macular Degeneration Product and Solutions
    Table 49. Genzyme Corporation Wet Macular Degeneration Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 50. Boehringer Ingelheim GmbH Corporate Information, Head Office, and Major Competitors
    Table 51. Boehringer Ingelheim GmbH Major Business
    Table 52. Boehringer Ingelheim GmbH Wet Macular Degeneration Product and Solutions
    Table 53. Boehringer Ingelheim GmbH Wet Macular Degeneration Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 54. EyeGate Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
    Table 55. EyeGate Pharmaceuticals, Inc. Major Business
    Table 56. EyeGate Pharmaceuticals, Inc. Wet Macular Degeneration Product and Solutions
    Table 57. EyeGate Pharmaceuticals, Inc. Wet Macular Degeneration Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 58. EyeCyte, Inc. Corporate Information, Head Office, and Major Competitors
    Table 59. EyeCyte, Inc. Major Business
    Table 60. EyeCyte, Inc. Wet Macular Degeneration Product and Solutions
    Table 61. EyeCyte, Inc. Wet Macular Degeneration Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 62. PanOptica Inc Corporate Information, Head Office, and Major Competitors
    Table 63. PanOptica Inc Major Business
    Table 64. PanOptica Inc Wet Macular Degeneration Product and Solutions
    Table 65. PanOptica Inc Wet Macular Degeneration Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 66. Global Wet Macular Degeneration Revenue (USD Million) by Players (2019-2021)
    Table 67. Global Wet Macular Degeneration Revenue Share by Players (2019-2021)
    Table 68. Breakdown of Wet Macular Degeneration by Company Type (Tier 1, Tier 2 and Tier 3)
    Table 69. Wet Macular Degeneration Players Head Office, Products and Services Provided
    Table 70. Wet Macular Degeneration Mergers & Acquisitions in the Past Five Years
    Table 71. Wet Macular Degeneration New Entrants and Expansion Plans
    Table 72. Global Wet Macular Degeneration Revenue (USD Million) by Type (2016-2021)
    Table 73. Global Wet Macular Degeneration Revenue Share by Type (2016-2021)
    Table 74. Global Wet Macular Degeneration Revenue Forecast by Type (2021-2026)
    Table 75. Global Wet Macular Degeneration Revenue by Application (2016-2021)
    Table 76. Global Wet Macular Degeneration Revenue Forecast by Application (2021-2026)
    Table 77. North America Wet Macular Degeneration Revenue by Type (2016-2021) & (USD Million)
    Table 78. North America Wet Macular Degeneration Revenue by Type (2021-2026) & (USD Million)
    Table 79. North America Wet Macular Degeneration Revenue by Application (2016-2021) & (USD Million)
    Table 80. North America Wet Macular Degeneration Revenue by Application (2021-2026) & (USD Million)
    Table 81. North America Wet Macular Degeneration Revenue by Country (2016-2021) & (USD Million)
    Table 82. North America Wet Macular Degeneration Revenue by Country (2021-2026) & (USD Million)
    Table 83. Europe Wet Macular Degeneration Revenue by Type (2016-2021) & (USD Million)
    Table 84. Europe Wet Macular Degeneration Revenue by Type (2021-2026) & (USD Million)
    Table 85. Europe Wet Macular Degeneration Revenue by Application (2016-2021) & (USD Million)
    Table 86. Europe Wet Macular Degeneration Revenue by Application (2021-2026) & (USD Million)
    Table 87. Europe Wet Macular Degeneration Revenue by Country (2016-2021) & (USD Million)
    Table 88. Europe Wet Macular Degeneration Revenue by Country (2021-2026) & (USD Million)
    Table 89. Asia-Pacific Wet Macular Degeneration Revenue by Type (2016-2021) & (USD Million)
    Table 90. Asia-Pacific Wet Macular Degeneration Revenue by Type (2021-2026) & (USD Million)
    Table 91. Asia-Pacific Wet Macular Degeneration Revenue by Application (2016-2021) & (USD Million)
    Table 92. Asia-Pacific Wet Macular Degeneration Revenue by Application (2021-2026) & (USD Million)
    Table 93. Asia-Pacific Wet Macular Degeneration Revenue by Region (2016-2021) & (USD Million)
    Table 94. Asia-Pacific Wet Macular Degeneration Revenue by Region (2021-2026) & (USD Million)
    Table 95. South America Wet Macular Degeneration Revenue by Type (2016-2021) & (USD Million)
    Table 96. South America Wet Macular Degeneration Revenue by Type (2021-2026) & (USD Million)
    Table 97. South America Wet Macular Degeneration Revenue by Application (2016-2021) & (USD Million)
    Table 98. South America Wet Macular Degeneration Revenue by Application (2021-2026) & (USD Million)
    Table 99. South America Wet Macular Degeneration Revenue by Country (2016-2021) & (USD Million)
    Table 100. South America Wet Macular Degeneration Revenue by Country (2021-2026) & (USD Million)
    Table 101. Middle East & Africa Wet Macular Degeneration Revenue by Type (2016-2021) & (USD Million)
    Table 102. Middle East & Africa Wet Macular Degeneration Revenue by Type (2021-2026) & (USD Million)
    Table 103. Middle East & Africa Wet Macular Degeneration Revenue by Application (2016-2021) & (USD Million)
    Table 104. Middle East & Africa Wet Macular Degeneration Revenue by Application (2021-2026) & (USD Million)
    Table 105. Middle East & Africa Wet Macular Degeneration Revenue by Country (2016-2021) & (USD Million)
    Table 106. Middle East & Africa Wet Macular Degeneration Revenue by Country (2021-2026) & (USD Million)
List of Figures
    Figure 1. Wet Macular Degeneration Picture
    Figure 2. Global Wet Macular Degeneration Revenue Market Share by Type in 2020
    Figure 3. Lucentis
    Figure 4. Eylea
    Figure 5. Avastin
    Figure 6. Others
    Figure 7. Wet Macular Degeneration Revenue Market Share by Application in 2020
    Figure 8. Hospitals Picture
    Figure 9. Clinics Picture
    Figure 10. Research Institutes Picture
    Figure 11. Academic Institutes Picture
    Figure 12. Global Wet Macular Degeneration Revenue, (USD Million): 2020 VS 2021 VS 2026
    Figure 13. Global Wet Macular Degeneration Revenue and Forecast (2016-2026) & (USD Million)
    Figure 14. Global Wet Macular Degeneration Revenue Market Share by Region (2016-2026)
    Figure 15. Global Wet Macular Degeneration Revenue Market Share by Region in 2020
    Figure 16. North America Wet Macular Degeneration Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 17. Europe Wet Macular Degeneration Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 18. Asia-Pacific Wet Macular Degeneration Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 19. South America Wet Macular Degeneration Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 20. Middle East and Africa Wet Macular Degeneration Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 21. Wet Macular Degeneration Market Drivers
    Figure 22. Wet Macular Degeneration Market Restraints
    Figure 23. Wet Macular Degeneration Market Trends
    Figure 24. Pfizer Inc. Recent Developments and Future Plans
    Figure 25. F. Hoffmann-La Roche AG Recent Developments and Future Plans
    Figure 26. Regeneron Pharmaceuticals, Inc. Recent Developments and Future Plans
    Figure 27. Novartis AG Recent Developments and Future Plans
    Figure 28. Bausch Health Companies Inc. Recent Developments and Future Plans
    Figure 29. Apellis Pharmaceuticals Inc. Recent Developments and Future Plans
    Figure 30. GlaxoSmithKline plc Recent Developments and Future Plans
    Figure 31. Ophthotech Corporation Recent Developments and Future Plans
    Figure 32. Gilead Sciences, Inc. Recent Developments and Future Plans
    Figure 33. Alcon Recent Developments and Future Plans
    Figure 34. Genzyme Corporation Recent Developments and Future Plans
    Figure 35. Boehringer Ingelheim GmbH Recent Developments and Future Plans
    Figure 36. EyeGate Pharmaceuticals, Inc. Recent Developments and Future Plans
    Figure 37. EyeCyte, Inc. Recent Developments and Future Plans
    Figure 38. PanOptica Inc Recent Developments and Future Plans
    Figure 39. Global Wet Macular Degeneration Revenue Share by Players in 2020
    Figure 40. Wet Macular Degeneration Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    Figure 41. Global Top 3 Players Wet Macular Degeneration Revenue Market Share in 2020
    Figure 42. Global Top 10 Players Wet Macular Degeneration Revenue Market Share in 2020
    Figure 43. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
    Figure 44. Global Wet Macular Degeneration Revenue Share by Type in 2020
    Figure 45. Global Wet Macular Degeneration Market Share Forecast by Type (2021-2026)
    Figure 46. Global Wet Macular Degeneration Revenue Share by Application in 2020
    Figure 47. Global Wet Macular Degeneration Market Share Forecast by Application (2021-2026)
    Figure 48. North America Wet Macular Degeneration Sales Market Share by Type (2016-2026)
    Figure 49. North America Wet Macular Degeneration Sales Market Share by Application (2016-2026)
    Figure 50. North America Wet Macular Degeneration Revenue Market Share by Country (2016-2026)
    Figure 51. United States Wet Macular Degeneration Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 52. Canada Wet Macular Degeneration Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 53. Mexico Wet Macular Degeneration Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 54. Europe Wet Macular Degeneration Sales Market Share by Type (2016-2026)
    Figure 55. Europe Wet Macular Degeneration Sales Market Share by Application (2016-2026)
    Figure 56. Europe Wet Macular Degeneration Revenue Market Share by Country (2016-2026)
    Figure 57. Germany Wet Macular Degeneration Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 58. France Wet Macular Degeneration Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 59. United Kingdom Wet Macular Degeneration Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 60. Russia Wet Macular Degeneration Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 61. Italy Wet Macular Degeneration Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 62. Asia-Pacific Wet Macular Degeneration Sales Market Share by Type (2016-2026)
    Figure 63. Asia-Pacific Wet Macular Degeneration Sales Market Share by Application (2016-2026)
    Figure 64. Asia-Pacific Wet Macular Degeneration Revenue Market Share by Region (2016-2026)
    Figure 65. China Wet Macular Degeneration Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 66. Japan Wet Macular Degeneration Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 67. South Korea Wet Macular Degeneration Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 68. India Wet Macular Degeneration Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 69. Southeast Asia Wet Macular Degeneration Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 70. Australia Wet Macular Degeneration Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 71. South America Wet Macular Degeneration Sales Market Share by Type (2016-2026)
    Figure 72. South America Wet Macular Degeneration Sales Market Share by Application (2016-2026)
    Figure 73. South America Wet Macular Degeneration Revenue Market Share by Country (2016-2026)
    Figure 74. Brazil Wet Macular Degeneration Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 75. Argentina Wet Macular Degeneration Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 76. Middle East and Africa Wet Macular Degeneration Sales Market Share by Type (2016-2026)
    Figure 77. Middle East and Africa Wet Macular Degeneration Sales Market Share by Application (2016-2026)
    Figure 78. Middle East and Africa Wet Macular Degeneration Revenue Market Share by Country (2016-2026)
    Figure 79. Turkey Wet Macular Degeneration Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 80. Saudi Arabia Wet Macular Degeneration Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 81. UAE Wet Macular Degeneration Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 82. Methodology
    Figure 83. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Pfizer Inc.
F. Hoffmann-La Roche AG
Regeneron Pharmaceuticals, Inc.
Novartis AG
Bausch Health Companies Inc.
Apellis Pharmaceuticals Inc.
GlaxoSmithKline plc
Ophthotech Corporation
Gilead Sciences, Inc.
Alcon
Genzyme Corporation
Boehringer Ingelheim GmbH
EyeGate Pharmaceuticals, Inc.
EyeCyte, Inc.
PanOptica Inc

Related Reports

Global Wet Macular Degeneration Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Global Wet Macular Degeneration Market 2022 by Company, Regions, Type and Application, Forecast to 2028

date 15 Jan 2022

date Pharma & Healthcare

Global Wet Macular Degeneration Supply, Demand and Key Producers, 2023-2029

Global Wet Macular Degeneration Supply, Demand and Key Producers, 2023-2029

date 01 Feb 2023

date Pharma & Healthcare

The global Wet Macular Degeneration market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Wet Macular Degeneration Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Wet Macular Degeneration Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 01 Jan 2023

date Pharma & Healthcare

Wet macular degeneration is a chronic eye disorder that induces vague vision or a blind spot in the patient's visual field.

Global Wet Macular Degeneration Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Wet Macular Degeneration Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 02 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Wet Macular Degeneration market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Product Tags

wet macular degeneration

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>